Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Elpipodect in Hepatic Impairment
NCT04676425Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Primary completion
- Jan 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial of elpipodect (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity and Maximum Observed Plasma Concentration. Started Mar 2021; status: completed.
02
Drugs
elpipodect
Beyond the preview
Go deeper on NCT04676425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676425.